InterMune, Inc. company was founded in 1998 and is headquartered in Brisbane, California. InterMune, Inc., a biotechnology company, focuses on the research, development, and commercialization of therapies in pulmonology and hepatology. It offers Actimmune for the treatment of patients with severe, malignant osteopetrosis, and chronic granulomatous disease in the United States. The company has a pipeline portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes CAPACITY, a Phase III program evaluating pirfenidone as a possible therapeutic candidate for the treatment of patients with IPF; and a research program focusing on pirfenidone analog ITMN-520. The hepatology portfolio comprises the HCV protease inhibitor compound ITMN-191, which is in Phase Ib, a second-generation HCV protease inhibitor research program; and a research program evaluating a new target in hepatology. It has license and collaboration agreements with Maxygen Holdings Ltd.; Array BioPharma, Inc.; Boehringer Ingelheim International GmbH; Hoffmann-LaRoche Inc. and F. Hoffmann-LaRoche Ltd.; Novartis Corporation; Connetics Corporation; Eli Lilly & Company; Genentech, Inc.; ALZA Corporation; Amgen Inc; and Marnac, Inc. and its co-licensor, /KDL GmbH.

Genfit SA, a biopharmaceutical company, develops therapies to reduce the cardiometabolic risk. The company focuses on the discovery and development of new chemical entities treating mainly dyslipidemia, atherosclerosis, diabetes, obesity, and inflammatory disorders. It has five programs in clinical phase of which, two are internal projects. The company’s internal projects consist of GFT14 that aims to target one of the major indications of cardiometabolic disease; and GFT505, a multimodal and pluripotent medicine indicated for atherogenic dyslipidemia for a patient who is overweight with or without diabetes. It develops its own drug candidates up to human proof of concept (Phase IIa). Genfit’s pipeline has various modes of action implying multimodal drugs and selective nuclear receptor modulation (SNuRM). The company also establishes partnerships with pharma groups on early-stage drug discovery programs. Its pharma alliances include Merck, Sanofi-Aventis, Solvay, Servier, and Pierre Fabre. Genfit was founded in 1999 and is headquartered in Loos, France with an additional office in Cambridge, the United States.

Senetek PLC (Senetek) is a life sciences company engaged in the development of technologies that target the science of healthy aging. The Company’s business consists of two business segments: dermatological/skincare compounds principally addressing photoaging and other skincare needs (Skincare), and pharmaceuticals, principally those addressing sales of monoclonal antibodies, sexual dysfunction and drug delivery of liquid injectable products (automatic injectors) (Pharmaceutical). The Skincare segment’s products include Pyratine-6, 4HBAP and Kinetin. The Pharmaceutical segment’s products include Invicorp, Reliaject, and diagnostic monoclonal antibodies used in Alzheimer’s and other disease research, which the Company licenses from Research Foundation for Mental Hygiene (RFMH) and sells to Covance Antibody Services Inc. The Company has three wholly owned subsidiaries, Senetek Drug Delivery Technologies Inc. (SSDT), Carme Cosmeceutical Sciences Inc. (CCSI) and Senetek Denmark ApS.

Cipla was founded as The Chemical, Industrial, & Pharmaceutical Laboratories by Khwaja Abdul Hamied in 1935; the founder's sons now head the company. Cipla is a market-leading medicine maker in India. The company has roughly 5,500 pharmaceutical products. Some are sold domestically, while the rest reach international markets in some 170 countries. It offers prescription drugs for all kinds of ailments -- arthritis, cancer, depression -- as well as over-the-counter drugs for colds, oral hygiene, and skin care. Cipla leads the domestic retail pharmaceutical market. The firm also makes bulk drugs, agrochemicals, and animal products. It has eight manufacturing plants located throughout the country.

When new drugs are tested, someone has to go first and Chiltern (Early Phase) Ltd. (formerly Drug Development Solutions) will help find that person. A contract research organization (CRO), the company specializes in bridging the gap between preclinical studies and the early stages of clinical trials in humans for drug candidates. Its clients include large multinational companies as well as small biotech startups. The company's facilities are based inside a major hospital with access to emergency medical care if needed. The company was spun off from the University of Dundee in 1982 and then acquired by CRO giant Chiltern International in 2008.

Futura Medical plc company, which develops pharmaceutical and other medical products for sexual dysfunctions in both men and women, uses the DermaSys technology in its MED2002 non-prescription topical gel being developed with GlaxoSmithKline as an erectile dysfunction product. Futura is exploring other applications for DermaSys as MED2002 continues clinical trials. Other products include CSD500, a device to reduce condom slippage, and FLD 500, the company's Female Lubrication Device that is globally marketed and distributed by SSL International.

Kendle International Inc. was founded in 1981 and is based in Cincinnati, Ohio. Kendle International Inc. is a global clinical research organization (CRO) that provides a range of Phase I-IV global clinical development services to the biopharmaceutical industry. The Company augments the research and development activities of biopharmaceutical companies by offering clinical research services and information technology designed to reduce drug development time and expense. Kendle International Inc. is managed in two reportable segments: Early Stage and Late Stage. The Early Stage business focuses on the Company’s Phase I operations while Late Stage is comprised of clinical development services related to Phase II through III clinical trials conducted worldwide, late phase clinical development services related to Phase IIIB and IV clinical trials conducted worldwide, regulatory affairs and biometrics offerings. In June 2008, the Company announced the acquisition of DecisionLine Clinical Research Corporation.

Bridgehead International wants to give its clients a head start. The consulting firm operates four divisions that provide a variety of services to a broad spectrum of life science companies and academic groups. Its transaction support division offers technical and commercial advice to firms developing new health care products. Healthcare education services creates medical education and communications programs for the pharmaceutical industry. The market access strategy segment helps companies evaluate competitive pricing and reimbursement models, while opportunity assessment helps firms understand the markets they are attempting to enter. The company operates across Europe, Asia, and North America.

Trimeris, Inc. was founded in 1993 and is based in Durham, North Carolina. Trimeris, Inc., a biopharmaceutical company, engages primarily in the commercialization of a class of fusion inhibitors for antiviral drug treatments. Its fusion inhibitors impair viral fusion, a complex process by which viruses attach to, penetrate, and infect host cells. The company offers FUZEON, a human immunodeficiency virus (HIV) fusion inhibitor and a 36-amino acid synthetic peptide that binds to a key region of an HIV surface protein called gp41 under a collaboration with F. Hoffmann-La Roche Ltd. Its FUZEON inhibitor blocks HIV viral fusion by interfering with certain structural rearrangements within gp41 that are required for HIV to fuse to and enter a host cell. FUZEON is approved in the United States, Canada, and the European Union. The company also holds TRI-1144, a next generation fusion inhibitor candidate that completed Phase I clinical trials.

Ikonisys is developing diagnostic tests for oncology and prenatal applications. Its lead product, fastFISH is a series of kits that help in identifying various prenatal conditions. FastFISH amnio is approved for identifying the chromosomal characteristics of birth defects such as Down syndrome, Edward's syndrome, and Patau syndrome. The company's oncoFish product line includes an FDA approved test for bladder cancer. The company is also developing a product can find chromosomal abnormalities in a fetus by testing the mother's blood, reducing the dangers associated with the standard, but invasive, amniocentesis procedure.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.